
Please try another search
Mochida Pharmaceutical Co., Ltd. manufactures and sells pharmaceuticals and healthcare products in Japan. It offers pharmaceuticals products for the treatment of cardiovascular, obstetrics, gynecology, dermatology, psychiatry, and gastroenterology, including Lialda, Omvoh, and Cortiment for the treatment of ulcerative colitis; Goofice and Movicol for the treatment of chronic constipation; Epadel for hyperlidemia and arteriosclerosis obliterans; Urece for gout and hyperuricemia; Treprost for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; Atelec, a calcium channel blocker; Dinagest, an agent for endometriosis, adenomyosis, and dysmenorrhea; Lexapro, an antidepressant; Tamcet, an analgesic for chronic pain; Beselna, a therapeutic agent for condyloma acuminatum and actinic keratosis; and Heparin Sodium MOCHIDA anticoagulant agents. The company also develops mesalazine for the treatment of ulcerative colitis; tocilizumab for the treatment of rheumatoid arthritis; dotinurad for the treatment of gout and hyperuricemia; dienogest formulation for dysmenorrhea; treprostinil for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; and icosapent for hypertriglyceridemia. In addition, it develops medical devices, including dMD-001 that is used for the treatment of articular cartilage lesions; dMD-002, which is used for the treatment of cavernous nerve injury; and dMD-003 for post-operative adhesion. Further, the company engages in the development, production, distribution, sale, and marketing of skincare products. Mochida Pharmaceutical Co., Ltd. was founded in 1913 and is headquartered in Tokyo, Japan.
Name | Age | Since | Title |
---|---|---|---|
Naoyuki Mochida | 66 | 1999 | President & Chairperson |
Yoshiharu Hashimoto | 62 | 2019 | Full-Time Audit & Supervisory Board Member |
Kyosuke Wagai | 72 | 2016 | Outside Audit & Supervisory Board Member |
Shigeaki Yoshikawa | 63 | 2023 | Independent Outside Director |
Tomoaki Sonoda | 64 | 2022 | Independent Outside Director |
Yoshifumi Miyata | 73 | 2021 | Outside Audit & Supervisory Board Member |
Mami Kobayashi | 61 | 2024 | Independent Outside Director |
Sanae Tanaka | 63 | 2025 | Independent Outside Director |
Masayoshi Takeda | 64 | 2022 | Full-Time Audit & Supervisory Board Member |
Akiko Suzuki | 76 | 2019 | Outside Audit & Supervisory Board Member |
Chu Sakata | 66 | 2011 | Director & Advisor |
Junichi Sakaki | 65 | 2014 | Senior Executive Managing Officer & Representative Director |
Yutaka Kawakami | 66 | 2019 | Executive Managing Officer Executive Director |
Junichi Nezu | 59 | 2023 | Executive Managing Officer & Director |
Motoi Mitsuishi | 62 | 2023 | Senior Executive Managing Officer & Representative Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review